AML With FLT3 Mutation
2 clinical trials · Condition
◉ Watch AML With FLT3 Mutation
| Record | Firm | Date |
|---|---|---|
| Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia (NCT07755202) | Florian Kuchenbauer | 2026-09-01 |
| A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation (NCT03182244) | Astellas Pharma Inc | 2017-10-25 |
Track AML With FLT3 Mutation automatically
Every clearance here is in the API, with alerts when new ones post.